Optimizing treatment of HER2-positive breast cancer

William J Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression-making metastatic disease far less common today-newer treatment advances are also impacting this disease. Dual targeting with pertuzumab and trastuzumab can extend the survival of metastatic disease by more 16 months, but despite such success, resistance to HER2 targeting remains a challenge. Drugs in the pipeline, such as neratinib, may help meet this therapeutic demand. In addition to anti-HER2 agents, chemotherapy is beneficial to patients with tumors 1 cm or larger, but the optimal treatment of smaller tumors is still a work in progress.

Original languageEnglish (US)
Pages (from-to)649-651
Number of pages3
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Optimizing treatment of HER2-positive breast cancer'. Together they form a unique fingerprint.

Cite this